Author's response to reviews

Title: How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

Authors:

Kaaren J Watts (k.watts@unsw.edu.au)
Bettina Meiser (b.meiser@unsw.edu.au)
Gillian Mitchell (gillian.mitchell@petermac.org)
Judy Kirk (judy.kirk@sydney.edu.au)
Christobel Saunders (christobel.saunders@uwa.edu.au)
Michelle Peate (michelle.peate@sydney.edu.au)
Jessica Duffy (jessica.duffy@sesiahs.health.nsw.gov.au)
Patrick Kelly (pkelly@health.usyd.edu.au)
Margaret Gleeson (Margaret.Gleeson@hnehealth.nsw.gov.au)
Kristine Barlow-Stewart (kristine.barlowstewart@sydney.edu.au)
Belinda Rahman (belinda.rahman@unsw.edu.au)
Michael Friedlander (m.friedlander@unsw.edu.au)
Kathy Tucker (kathy.tucker@sesiahs.health.nsw.gov.au)
for the TFGT Collaborative Group (k.watts@unsw.edu.au)

Version: 2 Date: 6 July 2012

Author's response to reviews: see over
6 July 2012

The Editor

BMC Cancer

Dear Sir/Madam,

Submission of MS: 9770799447578109 entitled:

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

Thank you for your email dated 5 July 2012 requesting changes to our manuscript submission.

We address each point you have raised in your email, below:

1. We confirm that our study is externally funded by a Priority-driven Collaborative Research Grant that is jointly supported by Cancer Australia, Cancer Council and the National Breast Cancer Foundation (ID 630405) to the total value of $594,540 over a period of three years. Please see the approval letter, attached. Our study has not received any funding or assistance from a commercial organization.

2. We have received ethical approval from each of the sites involved in this study. Please see the attached approval letters.

3. We confirm that there are no other manuscripts that are under submission with other journals based on this study protocol. This is the first manuscript to be generated from this study.

4. Our trial is registered in a suitable publicly accessible registry - the Australian and New Zealand Clinical Trials Group (Registration no: ACTRN12610000502033). I cannot determine whether the ANZCTG registry
complies with all of the ICMJE guidelines because I cannot access the URL http://ww.icmje.org/faq.pdf you have provided in your email.

5. We confirm that our authors have no competing interests to declare. We have amended the ‘Declaration of Competing Interests’ on p.24 of the manuscript to reflect this correctly.

6. On pp.22 and 23 we have amended the statement regarding the Authors’ Contributions to more accurately reflect their input and to comply with BMC Cancer’s requirements.

I have uploaded the revised version of the manuscript which includes the changes described in Points 5 and 6.

Many thanks for your consideration of this manuscript.

Yours sincerely,

Kaaren Watts, PhD
Psychosocial Research Group
Prince of Wales Hospital